A group of markers and their application in the differential diagnosis of benign and malignant thyroid follicular neoplasms

A technology of differential diagnosis and markers, applied in the field of biomedicine, can solve the problems of low sensitivity and specificity of benign and malignant judgment indicators, limited and lack of biological indicators of follicular tumors, and achieve the effect of avoiding overdiagnosis and treatment

Active Publication Date: 2022-02-08
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing indicators are mainly for papillary thyroid carcinoma, and the biological indicators for other follicular tumors are very limited, and there is a lack of experimental research with large sample size
In addition, the sensitivity and specificity of the existing benign and malignant judgment indicators are not high; and the existing indicators cannot predict the benign and malignant of borderline tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A group of markers and their application in the differential diagnosis of benign and malignant thyroid follicular neoplasms
  • A group of markers and their application in the differential diagnosis of benign and malignant thyroid follicular neoplasms
  • A group of markers and their application in the differential diagnosis of benign and malignant thyroid follicular neoplasms

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: Screening of methylation markers for benign and malignant thyroid tumors

[0044] The inventor collected paraffin wax specimens of thyroid follicular tumors diagnosed by the Department of Pathology of Peking Union Medical College Hospital between 2010 and 2016, a total of 128 cases (including 46 cases of FTA, 36 cases of TT-UMP and 46 cases of FTC), extracted DNA, and performed DNA analysis. Magnetic bead purification (Backman Ampure Xp beads); Methylation detection and analysis by bisulfite sequencing technology (RRBS), first look for differentially methylated molecules in the training set (consisting of 33 cases of FTA and 33 cases of FTC) .

[0045] Methylation detection and analysis was completed by Shanghai Kunyuan Biotechnology Co., Ltd.: take 100ng of purified sample DNA for enzyme digestion reaction, the reaction system is shown in Table 1, and the reaction temperature is as follows: 37°C for 3 hours, 80°C for 20 minutes, and 4°C for storage . Among...

Embodiment 2

[0053] Example 2 Using 70 differentially methylated markers to construct an assessment model for the potential of malignant thyroid cancer

[0054] After performing quality control analysis on the sequencing results of each sample in Example 1, the sequences of 70 marker segments were selected and calculated according to the calculation method of the methylation value corresponding to each marker (methylation value The calculation method refers to GuoS, et al. (2017) Identification of methylation haplotype blocks aids indeconvolution of heterogeneous tissue samples and tumor tissue-of-originmapping from plasma DNA. Nat Genet 49(4):635-642.), if there is a section If the sequencing depth of a certain CpG site is lower than 10×, the methylation value of this segment is NA. A sample-marker numerical matrix is ​​formed, and some exemplary data are shown in Table 3. The construction of the model was completed by Shanghai Kunyuan Biotechnology Co., Ltd.

[0055] Table 3 Marker met...

Embodiment 3

[0073] Example 3 Methylation Markers Used in the Differentiation of Benign and Malignant Thyroid Tumors

[0074] In this example, the model constructed in Example 2 was used to differentiate benign from malignant thyroid follicular tumor samples from 26 cases. The process is as follows:

[0075] According to the method of Example 2, a sample-marker numerical matrix of 26 samples similar to Table 3 was constructed.

[0076] Open the R program package and import the numerical matrix of 26 samples-markers to be evaluated

[0077] valdata=read.delim("storage path of sample-marker matrix", sep="\t", as.is=T, row.names=1, header=T, check.names=F)

[0078] Transpose the matrix into a matrix with row names of sample names and columns of methylation marker names

[0079] input=t(valdata)

[0080] And use the adjacent value complement method to make up the NA value

[0081] library(DMwR)

[0082] imputed = knnImputation(imput)

[0083] Reimport the established assessment model of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The present invention discloses a group of methylation markers for differential diagnosis and / or prediction of benign and malignant thyroid follicular tumors; further, the present invention provides the methylation markers in the preparation of benign and malignant thyroid follicular tumors for identification Applications in diagnostic tools. The present invention uses 128 paraffin tissue specimens of thyroid follicular lesions to find 70 thyroid follicular tumor-related methylation markers, which have very high sensitivity and specificity in judging benign and malignant thyroid follicular tumors (specificity 100%, the sensitivity is 92.3%, the accuracy is 96.2%, and the AUC value is 0.994); at the same time, the 70 markers can predict the benign and malignant borderline follicular thyroid tumors, and guide clinicians to make correct diagnosis and treatment strategies. Avoid overdiagnosis.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a group of markers for differential diagnosis of benign and malignant thyroid follicular tumors and applications thereof. Background technique [0002] Thyroid carcinoma (TC) is the most common endocrine malignancy, accounting for more than 95% of cases. Thyroid cancer mainly includes four pathological types (papillary thyroid carcinoma, follicular thyroid carcinoma, medullary carcinoma and anaplastic thyroid carcinoma). Follicular thyroid carcinoma (FTC) accounts for about 15% of all TCs and is a rare type of thyroid cancer. FTC is usually seen in older patients and is more aggressive than papillary thyroid carcinoma (PTC). The pathological diagnosis of FTC depends on the typical capsule and / or vascular invasion, while the tumor cells lack the characteristics of papillary carcinoma cell nuclei. [0003] Thyroid adenoma (FTA) is the most common benign thyroid follicular le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/11
CPCC12Q1/6886C12Q2600/154C12Q2600/112
Inventor 梁智勇张卉吴焕文任新瑜高洁陆俊良
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap